NewsCNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug admin1 year ago01 mins Source link Post Views: 38 Post navigation Previous: Triple combination COPD therapy lowers risk for cardiopulmonary outcomesNext: Critics Say FDA’s Use of Surrogate Markers Falling Short
